BiotechTube

Iohexol + Iodixanol + Iopromide + Ioversol

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hypothyroidism

Conditions

Hypothyroidism

Trial Timeline

Mar 1, 2022 → Feb 1, 2025

NCT ID
NCT03631771

About Iohexol + Iodixanol + Iopromide + Ioversol

Iohexol + Iodixanol + Iopromide + Ioversol is a approved stage product being developed by Bayer for Hypothyroidism. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03631771. Target conditions include Hypothyroidism.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03631771ApprovedWithdrawn

Competing Products

5 competing products in Hypothyroidism

See all competitors
ProductCompanyStageHype Score
Growth hormone + Growth hormone treatment and pubertyEli LillyApproved
85
Armour Thyroid + LevothyroxineAbbViePhase 2/3
65
iodinated contrast agentsBayerPre-clinical
20
Iodinated contrast agentsBayerPre-clinical
20
levothyroxine sodiumXeris PharmaceuticalsPhase 2
47

Other Products from Bayer

TelmisartanApproved
82
Clotrimazole vaginal tablet + FluconazoleApproved
82
Levitra (Vardenafil, BAY38-9456)Approved
82
Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved
82
Rivaroxaban 20 MG + WarfarinApproved
82